secondary end points included overall survival (OS) and safety.
introduction
Colorectal cancer (CRC) is in the top four most common cancers worldwide and was responsible for over 500 000 deaths in 2002 [1] . Up to 25% of CRC patients present with metastatic disease (mCRC), with the most common site for metastases being the liver [2] . An additional 35%-45% of patients will develop liver metastases during the course of their disease, with 20%-30% of patients having liver-limited metastases (LMCRC) [2, 3] . The prognosis for mCRC patients is poor with 5-year survival rates of 4% reported for untreated patients [4] and 3-year survival rates of 5%-10% in patients treated with palliative 5-fluorouracil (5-FU) and folinic acid (FA) [5] . A proportion of LMCRC patients are eligible for surgery with curative intent, which if successful has been reported to achieve 5-year survival rates of between 25% and 40% [6] [7] [8] . However, most treatment failures are due to local hepatic recurrences or metastases to the lungs, occurring within the first 2 years of surgery, raising the question of whether adjuvant therapy should be used in this setting.
Adjuvant 5-FU-based chemotherapy following surgery in patients suffering stage III CRC provides significant improvements in disease-free survival (DFS) and overall survival (OS) compared with surgery alone [9] [10] [11] , providing a rationale for its use in the adjuvant treatment of LMCRC patients following complete resection of metastases. A number of small studies indicate that significant patient benefit may be obtained from such an approach [12] [13] [14] [15] . In a study in which LMCRC patients were randomized to receive postoperative local hepatic arterial infusion (HAI) of floxuridine in combination with i.v. continuous 5-FU or surgery alone, a significant improvement in 4-year recurrence-free rate (46% versus 25%) was reported in patients receiving adjuvant therapy [15] . However, in a comparable larger study, adjuvant treatment was stopped due to toxicity associated with HIA [16] . More recently, Portier et al. [17] demonstrated in a multicenter randomized study, a significant improvement in 5-year DFS rate (33.5% versus 26.7%) in LMCRC following complete resection receiving systemic adjuvant 5-FU/FA compared with patients receiving surgery alone.
The combination of 5-FU/FA with irinotecan (FOLFIRI) has been reported to provide a significant improvement in the palliative treatment of mCRC patients compared with 5-FU/FA alone, with median survival times in excess of 20 months reported [18] [19] [20] [21] . A small phase II study reported tolerability of single-agent irinotecan in CRC patients previously treated with 5-FU following complete resection of colorectal hepatic metastasis [22] . However, there are currently no published randomized studies on the use of FOLFIRI in the adjuvant treatment of completely resectable LMCRC patients. In the present study, we report the results from a multicenter, randomized, phase III trial comparing FOLFIRI versus simplified 5-FU with leucovorin (LV, also known as FA) (LV5FUs) as adjuvant treatment in LMCRC patients following complete resection of metastases.
patients and methods

patient eligibility
Patient eligibility included histologically proven adenocarcinoma of the colon or rectum with complete resection of the primary tumor and complete resection (R0) of liver metastases within a minimum of 3 weeks and a maximum of 8 weeks before first study treatment. Only patients with exclusively hepatic metastases were included in the study. Patients were to have received baseline assessments including radiological assessment [abdominal-pelvic computed tomography (CT) scan] carried out before or after surgery for liver metastasis and clinical and carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) evaluations within a maximum of 14 days before study treatment. Prior adjuvant chemotherapy was allowed (excluding irinotecan-based therapy) if the last dose given was at least 3 months before first study treatment. Patients were required to be between 18 and 75 years of age (inclusive), with a World Health Organization performance status of two or less, with adequate hematological values and renal and liver function. Pregnant or breastfeeding patients were excluded together with patients who had any evidence of severe illness or medical condition other than CRC. Patients were also ineligible if they had any prior history of hepatic radiation or resection, radiofrequency ablation or cryoablation, prior chemotherapy for metastatic disease or a history (past or concurrent) of neoplasm other than CRC (except for those who were curatively treated disease free for >10 years). The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and written informed consent was obtained before the initiation of protocol procedures.
study design
This was a phase III randomized, open label, multicenter study to investigate the efficacy and safety of irinotecan in combination with LV5FUs in the adjuvant treatment of patients with LMCRC following R0 resection of liver metastases.
Eligible patients received on day 1, of a 2-week treatment cycle, a simplified De Gramont regimen [19, 23] Patients were randomized 1 : 1 and stratified by study center, number of metastases (1 versus 2-4 versus >4), prior chemotherapy (adjuvant versus nonadjuvant) and time from resection of primary tumor to the diagnosis of liver metastasis (£1 versus >1 year). The primary end point was DFS defined as the time interval between the date of randomization and the earliest date of local, regional or distant relapse or death due to cancer. Secondary end points were OS defined as the interval between the date of randomization and date of death from any cause and the safety of the treatment combination. During chemotherapy, patients were assessed by physical, hematological and biochemical evaluation every 6 weeks and CEA was measured and a CT scan carried every 3 months. These evaluations were carried out every 3 months within 2 years of last chemotherapy and every 6 months from 3-to 5-year post-chemotherapy. Safety was evaluated using treatment-emergent adverse events (AEs) graded according to the National Cancer Institute-Common Toxicity Criteria and the medical dictionary for regulatory activities, clinical laboratory data and physical examination at each cycle during treatment.
statistical considerations
The sample size calculation was based on the assumption of an increase in DFS from 32 months in the control arm (LV5FUs) to 50 months in the experimental arm (FOLFIRI). With a nominal one-sided a = 5% and 85% power, a total of 148 events were required. Assuming a uniform accrual rate of nine patients per month and exponential survival, it was estimated that with 420 patients, the required number of events would be observed 57 months after the start of the study. Due to a much lower accrual rate than expected (mean six patients per year, range 3-8), the trial was stopped to recruitment after 320 patients since it was estimated that the number of expected events would be observed after 1 year of follow-up for the last patient.
Time-to-event data were estimated using the Kaplan-Meier method [24] . DFS as well as OS were compared in the full analysis set, corresponding to patients who received treatment (minimum of one cycle) using the log-rank test. The Cox proportional hazards model was used to investigate treatment effect adjusted for covariates. The safety and AE data were collected after each cycle and reported as a maximum grade per patient. The reported P values are two sided and were considered significant at the 5% level. Fifteen patients were randomized but not treated, of these eight withdrew their consent, four had progressive disease before treatment and for two patients the delay between surgery and receiving chemotherapy was >8 weeks. One patient had neutropenia before treatment. After exclusion of these 15 patients, 153 patients received treatment (at least one cycle) in each arm and this group represents the full analysis population for efficacy (Figure 1 ). Other than study completion, the main reasons for patient discontinuation were relapse (higher in patients receiving LV5FUs; 10% versus 5%) and withdrawal of consent (higher in patients receiving FOLFIRI; 8% versus 2%).
One patient was randomized to receive LV5FUs, but inadvertently received two cycles of FOLFIRI. One patient treated with LV5FUs died within 30 days of treatment. The majority of patients in both treatment arms were male; 65% of patients receiving LV5FUs versus 59% of patients receiving FOLFIRI. The mean time from surgery of the primary tumor to randomization was similar for both treatment groups; LV5FUs versus FOLFIRI (15 versus 15.7 months). The majority of patients receiving prior adjuvant therapy received fluoropyrimidine and FA only. In arm A, three patients received oxaliplatin-containing regimens, while in arm B, two patients received oxaliplatin-containing regimens. Other baseline demographics and disease characteristics were well balanced between the treatment arms ( Table 1) .
treatment compliance
Of the patients receiving LV5FUs, 82% completed 12 cycles compared with 75% of patients receiving FOLFIRI which was not significantly different (supplemental Table 1 , available at Annals of Oncology online, Figure 1 ). Generally, patients receiving LV5FUs received cumulative higher doses of 5-FU/FA than those receiving FOLFIRI. Patients in the FOLFIRI arm had more cycles with dose reductions than patients in the LV5FUs arm (49% versus 18%); the main reason being hematological toxicity. Patients receiving FOLFIRI also experienced more treatment delays than those receiving LV5FUs (61% versus 54%).
efficacy
The median follow-up times were similar between patients receiving LV5FUs and FOLFIRI; 42.4 versus 41.7 months, respectively. Median DFS for patients receiving LV5FUs was 21.6 months which was not significantly different from 24.7 months observed in patients receiving FOLFIRI (Table 2) . Twoyear DFS rates were 46% for patients receiving LV5FUs compared with 51% for patients receiving FOLFIRI ( Figure  2A ). Median OS was not achieved; however, OS rates were comparable between the two arms with 3-year survival rates of 72% for patients treated with LV5FUs and 73% for those receiving FOLFIRI ( Figure 2B , Table 2 ). The treatment comparison for DFS was adjusted for the stratification factors using the Cox proportional hazards regression model (Table 3) . Patients randomized to FOLFIRI had a higher DFS rate compared with patients receiving LV5FUs, although this was not statistically significant [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.66-1.19; P = 0.44]. Prognostic factors associated with more favorable DFS were as follows: diagnosis of liver metastases >1 year following resection of the primary tumor (HR 0.59, 95% CI 0.41-0.84; P = 0.003) and the presence of only one liver metastasis (HR 0.74, 95% CI 0.55-1.00; P = 0.050). Patients who received prior adjuvant chemotherapy had a less favorable DFS (HR 1.39, 95% CI 1.0-1.95; P = 0.053). No significant interactions were observed between treatment and the three prognostic variables used for stratification.
In an unplanned exploratory analysis, in patients who received treatment within 6 weeks (n = 158) following resection of liver metastases those who received FOLFIRI (n = 78) had longer DFS than patients receiving LV5FUs (n = 80), although this was not statistically significant (HR 0.75; 95% CI 0.50-1.14, P = 0.17). However, no difference was observed in DFS times between treatment arms in patients receiving chemotherapy after 6 weeks following liver resection (HR 1.07; 95% CI 0.71-1.62, P = 0.75). original article
Randomized
patients n=321 LV5FUs n=160 FOLFIRI n=161 7 patients untreated 8 patients untreated Treated patients n=153 Treated patients n=153 Reason for study discontinuation Maximum no of cycles reached 125 Relapse 15 Adverse event 3 Consent withdrawn Death 1 Deviation from protocol 2 Other 4 Reason for study discontinuation Maximum no of cycles reached 115 Relapse 7 Adverse event 8 Consent withdrawn 3 1 2 Death 0 Deviation from protocol 2 Other 9
Annals of Oncology safety
The majority of treatment-related AEs were gastrointestinal and hematological, generally occurring more frequently and with greater severity in patients receiving FOLFIRI. The incidence of other AEs was similar between the treatment arms (Table 4) . Grade 3 or higher treatment-related AEs were recorded in 30% (45 of 152) of patients receiving LV5FUs, of which 6% (nine patients) met the criteria for serious AEs. Forty-seven percent (73 of 154) of patients receiving FOLFIRI had grade 3 or higher treatment-related AEs of which 13% (20 patients) were serious. Neutropenia was the most common grade 3 or higher toxicity in both treatment arms, with more patients receiving FOLFIRI developing grade 3 or higher neutropenia (23% versus 7%) and diarrhea (14% versus 7%) than those receiving LV5FUs (Table 4) . Of 11 patients discontinuing treatment due to toxicity, one of three patients in the LV5FUs arm and three of eight patients in the FOLFIRI arm discontinued due to In Europe and the United States, the routine treatment of patients suffering resectable LMCRC is resection of metastases, leading to 5-year survival rates of 25%-30% if R0 resection is achieved [6] [7] [8] . Often systemic adjuvant chemotherapy is given although there have been few clinical trials carried out to substantiate the benefit to patients of this practice. A number of small studies have reported significant improvements to patient benefit using adjuvant 5-FU/FA for patients with completely resectable LMCRC [12, 13, 15, 17] . These early findings have been supported with more recent data from larger studies [25, 26] and data from combined analysis of two phase III trials, in which LMCRC patients receiving adjuvant systemic infused 5-FU/FA had better median progression-free survival (PFS) (2.20 versus 1.55 years, HR 1.33, P = 0.059) than patients receiving surgery alone [27] . The improvement in DFS and OS times with the combination of irinotecan with 5-FU/FA in the first-line treatment of mCRC [18] [19] [20] provides the rationale for the use of adjuvant FOLFIRI compared with 5-FU/FA in completely resectable LMCRC patients.
In the present study, DFS was viewed as a suitable primary end point following phase III adjuvant 5-FU colon cancer trials, which demonstrate a strong correlation between median 3-year DFS and 5-year OS [28] . The median patient follow-up in the present study was 42 months for each treatment arm. Adjuvant FOLFIRI increased median DFS by 3 months compared with adjuvant LV5FUs in LMCRC patients and although this may be clinically meaningful, this was not statistically significant following multivariate analysis (HR 0.89, P = 0.44). No difference was observed on OS rates between the two treatment regimens. Clinical trials in mCRC are often problematic as clinical outcome following resection of liver metastasis can be affected by a variety of prognostic factors [29] . In patients with initially resectable LMCRC, decisions on what is technically resectable will also have a significant bearing on outcome [30, 31] . Common criteria to assess resectable disease is still evolving, thus patient heterogeneity can result following randomization in multicenter studies. As a consequence, published resection rates are mainly biased toward specialist centers. The most comprehensive guidelines for liver resection in LMCRC [32] were published in 2003 and these are being developed by the European Colorectal Cancer Metastasis Group to achieve a multidisciplinary treatment approach to patients with LMCRC, which can be adopted by all treatment centers [30, 31] .
In the present study, the following adverse factors on DFS were identified: diagnosis of liver metastasis <1 year following surgery of the primary tumor, more than one liver metastasis and prior adjuvant chemotherapy. Whether metastases are synchronous or metachronous will also influence patient prognosis or response to adjuvant chemotherapy. Wang et al. [33] reported improved survival in LMCRC patients with synchronous metastases (developing £6 months of diagnosis) treated with adjuvant 5-FU-based chemotherapy and HAI floxuridine-based chemotherapy but not in patients developing metachronous metastases (developing >6 months after diagnosis). The timing of the delivery of adjuvant chemotherapy following the resection of metastases may also be (7) 77 (51) 22 (14) 92 (60) Vomiting a 4 (3) 36 (24) 7 (5) an important factor to consider, as it is important for cytotoxic regimens to be used early in targeting actively growing micrometastases. This justifies our unplanned subgroup analysis of treatment effect according to the timing of surgery for metastases and the start of chemotherapy. There was a tendency for improvement in DFS for patients who received FOLFIRI within 6 weeks of resection for liver metastasis as compared with LV5FUs, whereas there was no difference in DFS between the treatment regimens for patients who received chemotherapy >6 weeks after the resection of liver metastasis. Treatment outcome was also investigated for the different subgroups of stratification factors and no significant treatment by covariate interaction was found.
The toxicity profile of FOLFIRI in adjuvant LMCRC was similar to that previously reported in both adjuvant CRC and palliative mCRC [20, 34] , with grade 3/4 neutropenia being more common with FOLFIRI than LV5FUs. In the present study, patients receiving adjuvant FOLFIRI received significantly lower median relative dose intensities for 5-FU and had a significantly increased number of patients receiving cycles with reduced treatment doses than patients receiving 5-FU/FA.
There is currently no evidence that combination therapies offer significant additional benefit to 5-FU-based chemotherapy in adjuvant treatment of resectable LMCRC patients [34, 35] . Data from the EORTC intergroup trial indicate that perioperative therapy with FOLFOX-4 is compatible with liver surgery and reduces the risk of events of PFS in eligible and resected patients but in this trial chemotherapy was compared with surgery alone and not to 5-FU/FA [36] . There is a need for larger clinical trials to investigate new combinations of cytotoxic drugs and targeted agents. In a recent nonrandomized phase II study, neoadjuvant XELOX in combination with bevacizumab was investigated in 52 mCRC patients with resectable liver metastases with a high risk of recurrence. It was found that this combination could be safely administered, with objective responses achieved in 73% of patients, 52% undergoing liver resection with no effect recorded on liver regeneration from the use of bevacizumab [37] . Recent reports from randomized clinical trials with anti-EGFR-targeted mAbs (cetuximab and panitumumab) show significant improvements in clinical benefit in patients whose tumors harbor nonmutated KRAS (for codons 12 and 13) alleles [38] [39] [40] . Thus, considerations for tailoring combination therapies in the adjuvant treatment of LMCRC to patients who will receive most benefit will need to be integrated into future trials.
In conclusion, the use of FOLFIRI in adjuvant LMCRC following complete resection of liver metastasis does not significantly improve patient DFS compared with treatment with LV5FUs, although we cannot exclude a positive effect of FOLFIRI on DFS if it is administered within 6 weeks following surgery.
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